TY - JOUR
T1 - Thrombin-Fibrin(ogen) Interactions, Host Defense and Risk of Thrombosis
AU - Hulshof, Anne-Marije
AU - Hemker, H Coenraad
AU - Spronk, Henri M H
AU - Henskens, Yvonne M C
AU - Ten Cate, Hugo
N1 - Funding Information:
Conflicts of Interest: Henri M.H. Spronk received research funding from Bayer and is stockholder with Coagulation Profile. Hugo ten Cate received research funding from Bayer and Pfizer, is consultant for Alveron and stockholder with Coagulation Profile. The authors declare no conflict of interest.
Funding Information:
Funding: This research received no external funding; current research related to COVID‐19 associated coagulopathy is part of the Dutch COVID and Thrombosis Coalition (DCTC), supported by ZON‐MW and the Thrombosis Foundation.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/3/4
Y1 - 2021/3/4
N2 - Fibrinogen is a well-known risk factor for arterial and venous thrombosis. Its function is not restricted to clot formation, however, as it partakes in a complex interplay between thrombin, soluble plasma fibrinogen, and deposited fibrin matrices. Fibrinogen, like thrombin, participates predominantly in hemostasis to maintain vascular integrity, but executes some important pleiotropic effects: firstly, as observed in thrombin generation experiments, fibrin removes thrombin from free solution by adsorption. The adsorbed thrombin is protected from antithrombins, notably α2-macroglobulin, and remains physiologically active as it can activate factors V, VIII, and platelets. Secondly, immobilized fibrinogen or fibrin matrices activate monocytes/macrophages and neutrophils via Mac-1 interactions. Immobilized fibrin(ogen) thereby elicits a pro-inflammatory response with a reciprocal stimulating effect of the immune system on coagulation. In contrast, soluble fibrinogen prohibits recruitment of these immune cells. Thus, while fibrin matrices elicit a procoagulant response, both directly by protecting thrombin and indirectly through the immune system, high soluble fibrinogen levels might protect patients due to its immune diminutive function. The in vivo influence of the 'protective' plasma fibrinogen versus the 'pro-thrombotic' fibrin matrices on thrombosis should be explored in future research.
AB - Fibrinogen is a well-known risk factor for arterial and venous thrombosis. Its function is not restricted to clot formation, however, as it partakes in a complex interplay between thrombin, soluble plasma fibrinogen, and deposited fibrin matrices. Fibrinogen, like thrombin, participates predominantly in hemostasis to maintain vascular integrity, but executes some important pleiotropic effects: firstly, as observed in thrombin generation experiments, fibrin removes thrombin from free solution by adsorption. The adsorbed thrombin is protected from antithrombins, notably α2-macroglobulin, and remains physiologically active as it can activate factors V, VIII, and platelets. Secondly, immobilized fibrinogen or fibrin matrices activate monocytes/macrophages and neutrophils via Mac-1 interactions. Immobilized fibrin(ogen) thereby elicits a pro-inflammatory response with a reciprocal stimulating effect of the immune system on coagulation. In contrast, soluble fibrinogen prohibits recruitment of these immune cells. Thus, while fibrin matrices elicit a procoagulant response, both directly by protecting thrombin and indirectly through the immune system, high soluble fibrinogen levels might protect patients due to its immune diminutive function. The in vivo influence of the 'protective' plasma fibrinogen versus the 'pro-thrombotic' fibrin matrices on thrombosis should be explored in future research.
KW - Animals
KW - Fibrin/metabolism
KW - Fibrinogen/metabolism
KW - Hemostasis/physiology
KW - Humans
KW - Immune System/metabolism
KW - Thrombin/metabolism
KW - Thrombosis/metabolism
KW - thrombin
KW - fibrinogen
KW - inflammatory disease
KW - thrombin generation assay
KW - immune system
U2 - 10.3390/ijms22052590
DO - 10.3390/ijms22052590
M3 - (Systematic) Review article
C2 - 33806700
SN - 1661-6596
VL - 22
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 5
M1 - 2590
ER -